Navegando por Palavras-chave "Carbamazepine"

Agora exibindo 1 - 4 de 4
  • Imagem de Miniatura
    Item
    Acesso aberto (Open Access)
    Carbamazepine inhibits angiotensin I-converting enzyme, linking it to the pathogenesis of temporal lobe epilepsy
    (Nature Publishing Group, 2012-03-01) Almeida, Sandro Soares [UNIFESP]; Naffah-Mazzacoratti, Maria da Graca [UNIFESP]; Guimarães, Paola Bianchi [UNIFESP]; Wasinski, Frederick [UNIFESP]; Pereira, Flavia Enira Gomes [UNIFESP]; Canzian, Mauro [UNIFESP]; Centeno, Ricardo Silva [UNIFESP]; Carrete Junior, Henrique [UNIFESP]; Yacubian, Elza Márcia Targas [UNIFESP]; Carmona, Adriana Karaoglanovic [UNIFESP]; Vieira, Renata de Freitas Fischer [UNIFESP]; Nakaie, Clovis Ryuichi [UNIFESP]; Sabatini, Regiane Angelica [UNIFESP]; Perosa, Sandra Regina [UNIFESP]; Bacurau, Reury Frank Pereira; Gouveia, Telma Luciana Furtado [UNIFESP]; Gallo, Gloria [UNIFESP]; Wuertele, Martin [UNIFESP]; Cavalheiro, Esper Abrão [UNIFESP]; Silva Junior, Jose Antonio [UNIFESP]; Pesquero, João Bosco [UNIFESP]; Araujo, Ronaldo de Carvalho [UNIFESP]; Universidade Federal de São Paulo (UNIFESP); Universidade de São Paulo (USP); Nove de Julho Univ UNINOVE
    We find that a common mutation that increases angiotensin I-converting enzyme activity occurs with higher frequency in male patients suffering from refractory temporal lobe epilepsy. However, in their brains, the activity of the enzyme is downregulated. As an explanation, we surprisingly find that carbamazepine, commonly used to treat epilepsy, is an inhibitor of the enzyme, thus providing a direct link between epilepsy and the renin-angiotensin and kallikrein-kinin systems. Translational Psychiatry (2012) 2, e93; doi:10.1038/tp.2012.21; published online 13 March 2012
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Carbamazepine-exposure during gestation and lactation affects pubertal onset and spermatic parameters in male pubertal offspring
    (Elsevier B.V., 2014-04-01) Andretta, Rhayza Roberta [UNIFESP]; Okada, Fatima Kazue [UNIFESP]; Paccola, Camila Cicconi [UNIFESP]; Stumpp, Taiza [UNIFESP]; Oliva, Samara Urban de [UNIFESP]; Miraglia, Sandra M. [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)
    Carbamazepine (CBZ) is an anti-epileptic drug that acts on Leydig cells, affecting steroidogenesis and causes fetal malformation. the aim of this study was to investigate the effects of CBZ on male sexual maturation and other male parameters. Rat dams were treated with CBZ during pregnancy and breastfeeding. the anogenital distance (AGD) and the anogenital index (AGI) were obtained. Testicular descent and preputial separation were also evaluated. the offspring was euthanized at PND 41 and 63. the accessory glands were weighed and the testes were collected for histopathological, morphometric and sterological analyses. the numerical density of Leydig cells and hormone dosage were obtained. CBZ caused an increase of AGI and a delay of testicular descent and of preputial separation. CBZ also caused a decrease of testosterone level and of sperm count and an increase of abnormal sperm. These results indicate that CBZ delays puberty onset and affects steroidogenesis and sperm quality. (C) 2013 Elsevier Inc. All rights reserved.
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Harmful effects of carbamazepine on the postnatal development of the rat ventral prostate
    (Biomed Central Ltd, 2012-03-25) Oliva, Samara Urban de [UNIFESP]; Scarano, Wellerson Rodrigo; Okada, Fatima Kazue [UNIFESP]; Miraglia, Sandra Maria [UNIFESP]; Universidade de São Paulo (USP); Universidade Federal de São Paulo (UNIFESP)
    Background: Carbamazepine (CBZ) is a first-line antiepileptic drug (AED), although it is also used for the treatments of psychiatric disorders and neuropathic pain. the CBZ utilization has been associated with male reproductive damage, including hormonal alterations, sexual dysfunction and reduction of sperm quality. the wide and long-term use of the CBZ is a common schedule in children and adolescents and alters the testosterone level in adult rats and humans. the objective of this work was to evaluate the CBZ side effects on the ventral prostate of rats from pre-puberty to sexual maturation, since the prostate is an androgen-dependent organ.Methods: Twenty three day-old male albino Wistar rats received CBZ diluted in propylene glycol (20 mg/Kg/i.p via). the treatment lasted 20, 40 and 70 days, according to the different stages of the rat sexual maturation. At the end of each treatment period, ventral prostates were removed and histologically processed. the prostate sections were submitted to the histopathological, morphological and stereological analyses using image analysis system.Results: Reductions of the glandular epithelium, glandular lumen and fibromuscular stroma volume of the ventral prostate were observed in adult rats treated with CBZ since the weaning. Triggering and degranulation of mast cells were observed in the fibromuscular stroma of prepubertal and pubertal CBZ treated rats.Conclusions: the results suggest a direct effect of the CBZ on rat ventral prostate, evidenced by increase of mast cell and macrophage populations during pre-puberty and puberty causing a ventral prostate accentuated damage in the adult phase.
  • Imagem de Miniatura
    Item
    Acesso aberto (Open Access)
    Pharmacological treatment for kleine-levin syndrome
    (Wiley-blackwell, 2016) de Oliveira, Marcio M. [UNIFESP]; Conti, Cristiane [UNIFESP]; Prado, Gilmar F. [UNIFESP]
    Background This is an updated version of the original Cochrane review, published in 2009, Issue 2. Kleine-Levin syndrome (KLS) is a rare disorder that mainly affects adolescent men. It is characterised by recurrent episodes of hypersomnia, usually accompanied by hyperphagia, cognitive and mood disturbances, abnormal behaviour, such as hypersexuality, and signs of dysautonomia. In 1990, the diagnostic criteria for Kleine-Levin syndrome were modified in the International Classification of Sleep Disorders, where KLS was defined as a syndrome comprised of recurring episodes of undue sleepiness lasting some days, which may or may not be associated with hyperphagia and abnormal behaviour. According to the International Classification of Sleepiness Disorders, 3rd version (ICSD-3), revised in 2014, the Kleine-Levin syndrome is a disorder characterized by recurrent episodes of hypersomnia that last from two days to four weeks, with at least annual recurrence, and hyperphagia (rapid consumption of a large amount of food), usually with onset in early adolescence in males but occasionally in later life and in women. A monosymptomatic form of the disorder with hypersomnia only can occur without binge eating or hypersexuality. The cause of Kleine-Levin syndrome remains unknown, and several treatment strategies have been used. Some medications have been reported to provide benefit in the treatment of patients with KLS, but because of the rarity of the condition, no long-term follow-up therapies have yet been described. Objectives This review aimed to evaluate: 1. whether pharmacological treatment for Kleine Levin syndrome was effective and safe. 2. which drug or category of drugs was effective and safe. Search methods For the latest update, we searched the following sources: the Cochrane Epilepsy Group Specialized Register (7 April 2016)